(Q36676064)

15 August 2017

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications (English)

1 reference

15 August 2017

20

Cliona M Rooney

1 reference

15 August 2017

Natalia Lapteva

1

1 reference

15 August 2017

April G Durett

2

1 reference

15 August 2017

Jiali Sun

3

1 reference

15 August 2017

Lisa A Rollins

4

1 reference

15 August 2017

Leslie L Huye

5

1 reference

15 August 2017

Jian Fang

6

1 reference

15 August 2017

Varada Dandekar

7

1 reference

15 August 2017

Zhuyong Mei

8

1 reference

15 August 2017

Kimberley Jackson

9

1 reference

15 August 2017

Juan Vera

10

1 reference

15 August 2017

Jun Ando

11

1 reference

15 August 2017

Minhtran C Ngo

12

1 reference

15 August 2017

Elaine Coustan-Smith

13

1 reference

15 August 2017

Dario Campana

14

1 reference

15 August 2017

Susann Szmania

15

1 reference

15 August 2017

Tarun Garg

16

1 reference

15 August 2017

Amberly Moreno-Bost

17

1 reference

15 August 2017

Frits Vanrhee

18

1 reference

15 August 2017

Adrian P Gee

19

1 reference

15 August 2017

17 August 2012

1 reference

15 August 2017

1 reference

15 August 2017

14

1 reference

15 August 2017

9

1 reference

15 August 2017

1131-1143

1 reference

A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Optimization manufacture of virus- and tumor-specific T cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Expansion, purification, and functional assessment of human peripheral blood NK cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Natural killer cell-directed therapies: moving from unexpected results to successful strategies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

A potential role for interleukin-15 in the regulation of human natural killer cell survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Induction of the expression of HLA class I antigens on K562 by interferons and sodium butyrate

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Synergistic enhancement of class I major histocompatibility complex antigen expression in K562 cells induced by recombinant human interferon-gamma and tumor necrosis factor in combination.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Evaluation of natural killer cell activity in pre and post treated breast cancer patients.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Ex vivo expansion of natural killer cells for clinical applications

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787300

A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells

20 September 2018

1 reference

12 December 2020

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

1 reference

12 December 2020

Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer

1 reference

12 December 2020

HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon

1 reference

12 December 2020

Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy

1 reference

12 December 2020

A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells

1 reference

12 December 2020

Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals

1 reference

12 December 2020

Role of monocytes in the expansion of human activated natural killer cells

1 reference

12 December 2020

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

1 reference

12 December 2020

Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients

1 reference

12 December 2020

Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer

1 reference

12 December 2020

10.3109/14653249.2012.700767

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

22900959

1 reference